Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To evaluatre the risk of immunogenicity in patients with chronic inflammatory diseases who experienced successive non-medical swiches to different biosimilars infliximab.
Patients And Methods: Observational study over a 3-year observation period assessing the risk of immunogenicity in i) patients in maintenance therapy with innovator infliximab who were successively switched to CT-P13, then to SB2 (cohort-1) and ii) biologic-naive patients initiated with CT-P13 before being switched to SB2 (cohort-2). A propotion meta-analysis was also performed, integrating our results to 16 additional studies.
Results: Cohort-1 included 265 patients who switched to CT-P13, and 140 patients were subsequently switched to SB2. Among the 235 anti-drug antibody (ADA)-free patients at baseline, 20 patients (8.5%) developed ADA over the 3-year observation period (rate of 3 for 100 patient years). Cohort-2 included 44 patients, of whom 29 subsequently switched to SB2. A total of 11 patients (25%) developed ADA within 3 years (rate of 14 for 100 patients years). We found no influence of the number of biosimilars infliximab received on ADA deveopment in both cohorts. The risk of treatment discontinuation was significantly higher in patients with positive ADA in both cohorts. The meta-analysis including our data exposed an incidence of immunogenicity of 4.7% (95% CI 3.5-6.1%) after the switch from innovator infliximab to biosimilar infliximab and 21.1% (95% CI 13.1-30.3%) in patients initiating biosimilar infliximab.
Conclusion: Immunogenicity was not favored by successive non-medical switches to biosimilars infliximab in our study, but was associated with treatment discontinuation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.semarthrit.2020.02.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study.
Inflamm Bowel Dis
September 2025
IBD Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy.
Background: The infliximab (IFX) biosimilar, CT-P13, is available as an intravenous (IV) and subcutaneous (SC) formulation. Although current indications allow the transition from IV CT-P13 to SC CT-P13 after two IV administrations, some clinicians prefer to postpone switching until stable clinical remission has been achieved.
Methods: We evaluate the endoscopic response, treatment persistence, clinical remission, endoscopic remission, and safety profile after one year of treatment with IFX in patients switched from IV to SC after 6 weeks (early switch group) or after 6 months (late switch group).
Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management.
Expert Opin Biol Ther
September 2025
Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Introduction: The introduction of biosimilars changed the management of biologicals in inflammatory bowel disease (IBD) since the approval of CT-P13, the first biosimilar to infliximab, by the European Medicines Agency (EMA) in September 2013 and by the U.S. Food and Drug Administration (FDA) in April 2016.
View Article and Find Full Text PDFDiscontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): A clinical, ultrasound, and biomarker-based effectiveness after discontinuation and reinitiation of biosimilar infliximab.
Glob Health Med
August 2025
Departments of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting synovial joints. Biosimilar disease-modifying anti-rheumatic drugs offer cost-effective alternatives to originator biologics for RA treatment but remain expensive for long-term use. This prospective study investigated the clinical benefit of discontinuing CT-P13, a biosimilar of infliximab, in RA patients maintaining clinical remission or low disease activity.
View Article and Find Full Text PDFMedicines Policy in Action: The Impact on Volume and Cost of Biologic Medicines After Biosimilar Introduction.
Value Health Reg Issues
August 2025
Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Australia.
Objectives: Rapid growth in indications and costs for biologic medicines challenges payers to balance patient access with finite health budgets. Once patents for reference products expire, introducing less expensive biosimilar medicines is one initiative to provide access to necessary medicines while maintaining the affordability of funding schemes. This study aims to describe the impact on volume and cost of biosimilars on the Australian biologics market.
View Article and Find Full Text PDFBiosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
Psoriasis (Auckl)
August 2025
Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
Psoriasis is an immune-mediated chronic inflammatory skin disease affecting over 60 million adults and children worldwide and can occur at any age, from childhood to adulthood. If the patient has a diffuse form of psoriasis, affecting more than ten percent of the body surface, or involving sensitive areas such as the face, scalp, nails, and/or palmoplantar region, he or she is a candidate for systemic therapy. Currently, several drugs are approved for the treatment of moderate to severe chronic plaque psoriasis in Europe and US.
View Article and Find Full Text PDF